ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments (2023 - 2026)

ARS Pharmaceuticals (SPRY) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $42.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 33.07% year-over-year to $42.5 million; the trailing twelve-month figure through Mar 2026 stood at $286.0 million (up 7.32% YoY), and the FY2025 full-year result was $307.0 million, up 18.99% from the prior year.
• Change in Acquisitions & Divestments declined to $42.5 million in Q1 2026, from $75.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $88.5 million in Q3 2025 to a low of $20.0 million in Q1 2023.
• A 4-year average of $61.0 million and a median of $61.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments soared 175.0% in 2024 and sank 33.07% in 2026, its largest moves.
• Tracing SPRY's Change in Acquisitions & Divestments over 4 years: stood at $60.0 million in 2023, then grew by 11.67% to $67.0 million in 2024, then rose by 11.94% to $75.0 million in 2025, then sank by 43.33% to $42.5 million in 2026.
• Business Quant data shows SPRY's Change in Acquisitions & Divestments at $42.5 million in Q1 2026, $75.0 million in Q4 2025, and $88.5 million in Q3 2025.